Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

BMS-986278

Status:

Phase 3

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Industry

Drug Details

BMS-986278 is a potent lysophospholipid receptor antagonist (LPA1).

IPF Study Purpose

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis (IPF).

Find a Clinical Trial

PPF Study Purpose

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (PPF).

Find a Clinical Trial